targetprint her2 gene expression (Agendia BV)
90
Structured Review
Agendia BV
targetprint her2 gene expression
Targetprint Her2 Gene Expression, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/microarray+based+assay+of+her2+expression+targetprint/pmc05259561-162-8-14
Average 90 stars, based on 1 article reviews
Targetprint Her2 Gene Expression, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/microarray+based+assay+of+her2+expression+targetprint/pmc05259561-162-8-14
Average 90 stars, based on 1 article reviews
targetprint her2 gene expression - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer"
Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Journal: The New England journal of medicine
doi: 10.1056/NEJMoa1513749
Figure Legend Snippet: Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if HER2+) cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Techniques Used:
Figure Legend Snippet: Only patients with HER2-negative disease were eligible for randomization to the VC arm. Patients were categorized as received allocated invention if they received at least one dose of experimental (or control) therapy.
Techniques Used:
Figure Legend Snippet: Estimated pCR Rate for the signatures evaluated for V/C vs. concurrent HER2-negative control.
Techniques Used: Negative Control
Figure Legend Snippet: Final predictive probabilities
Techniques Used:
Figure Legend Snippet: Selected Toxicities
Techniques Used:
Related Articles
Microarray:Article Title: Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. Article Snippet: Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization Monica Sager, Nai Chien Yeat, Stefan Pajaro-Van der Stadt, Charlotte Lin, Qiuyin Ren & Jimmy Lin To cite this article: Monica Sager, Nai Chien Yeat, Stefan Pajaro-Van der Stadt, Charlotte Lin, Qiuyin Ren & Jimmy Lin (2015): Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization, Expert Review of Molecular Diagnostics, DOI: 10.1586/14737159.2015.1105133 To link to this article: http://dx.doi.org/10.1586/14737159.2015.1105133 Article Title: Additive value of diffusion weighted MRI in the I-SPY 2 TRIAL Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−) and human epidermal growth factor receptor 2 (HER2+/−) status and a 70-gene assay (MammaPrint, Agendia) were performed at the baseline and used for treatment randomization 6 . .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray-based assay of Article Title: Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−), human epidermal growth factor receptor 2 (HER2+/−) status, and a 70‐gene assay (MammaPrint, Agendia, Amsterdam, The Netherlands) were performed at baseline (T0) and used for treatment randomization ( ). .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray‐based assay of Article Title: Adaptive Randomization of Neratinib in Early Breast Cancer Article Snippet: .. Biomarker assessments include the Agendia 70 gene MammaPrint and Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and Expressing:Article Title: Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. Article Snippet: Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization Monica Sager, Nai Chien Yeat, Stefan Pajaro-Van der Stadt, Charlotte Lin, Qiuyin Ren & Jimmy Lin To cite this article: Monica Sager, Nai Chien Yeat, Stefan Pajaro-Van der Stadt, Charlotte Lin, Qiuyin Ren & Jimmy Lin (2015): Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization, Expert Review of Molecular Diagnostics, DOI: 10.1586/14737159.2015.1105133 To link to this article: http://dx.doi.org/10.1586/14737159.2015.1105133 Article Title: Additive value of diffusion weighted MRI in the I-SPY 2 TRIAL Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−) and human epidermal growth factor receptor 2 (HER2+/−) status and a 70-gene assay (MammaPrint, Agendia) were performed at the baseline and used for treatment randomization 6 . .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray-based assay of Article Title: Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−), human epidermal growth factor receptor 2 (HER2+/−) status, and a 70‐gene assay (MammaPrint, Agendia, Amsterdam, The Netherlands) were performed at baseline (T0) and used for treatment randomization ( ). .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray‐based assay of Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and Gene Expression:Article Title: Biomarker assessment and molecular testing for prognostication in breast cancer. Article Snippet: Current treatment of breast cancer incorporates clinical, pathological and molecular data.. Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) define prognosis and identify tumours for targeted therapy, and remain the sole established single-molecule biomarkers defining the minimum breast cancer pathology data set.. Ki67 remains one of the most promising yet controversial biomarkers in breast cancer, implemented routinely in some, but not all, pathology departments. Article Title: Adaptive Randomization of Neratinib in Early Breast Cancer Article Snippet: .. Biomarker assessments include the Agendia 70 gene MammaPrint and Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and Immunohistochemical staining:Article Title: Additive value of diffusion weighted MRI in the I-SPY 2 TRIAL Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−) and human epidermal growth factor receptor 2 (HER2+/−) status and a 70-gene assay (MammaPrint, Agendia) were performed at the baseline and used for treatment randomization 6 . .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray-based assay of Article Title: Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−), human epidermal growth factor receptor 2 (HER2+/−) status, and a 70‐gene assay (MammaPrint, Agendia, Amsterdam, The Netherlands) were performed at baseline (T0) and used for treatment randomization ( ). .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray‐based assay of Fluorescence:Article Title: Additive value of diffusion weighted MRI in the I-SPY 2 TRIAL Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−) and human epidermal growth factor receptor 2 (HER2+/−) status and a 70-gene assay (MammaPrint, Agendia) were performed at the baseline and used for treatment randomization 6 . .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray-based assay of Article Title: Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−), human epidermal growth factor receptor 2 (HER2+/−) status, and a 70‐gene assay (MammaPrint, Agendia, Amsterdam, The Netherlands) were performed at baseline (T0) and used for treatment randomization ( ). .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray‐based assay of In Situ Hybridization:Article Title: Additive value of diffusion weighted MRI in the I-SPY 2 TRIAL Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−) and human epidermal growth factor receptor 2 (HER2+/−) status and a 70-gene assay (MammaPrint, Agendia) were performed at the baseline and used for treatment randomization 6 . .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray-based assay of Article Title: Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−), human epidermal growth factor receptor 2 (HER2+/−) status, and a 70‐gene assay (MammaPrint, Agendia, Amsterdam, The Netherlands) were performed at baseline (T0) and used for treatment randomization ( ). .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray‐based assay of Fluorescence In Situ Hybridization:Article Title: Additive value of diffusion weighted MRI in the I-SPY 2 TRIAL Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−) and human epidermal growth factor receptor 2 (HER2+/−) status and a 70-gene assay (MammaPrint, Agendia) were performed at the baseline and used for treatment randomization 6 . .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray-based assay of Article Title: Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy Article Snippet: Biomarker assessments based on hormone (estrogen and progesterone) receptors (HR+/−), human epidermal growth factor receptor 2 (HER2+/−) status, and a 70‐gene assay (MammaPrint, Agendia, Amsterdam, The Netherlands) were performed at baseline (T0) and used for treatment randomization ( ). .. In addition to standard immunohistochemical and fluorescence in situ hybridization (FISH) assays, the protocol included a microarray‐based assay of Biomarker Discovery:Article Title: Adaptive Randomization of Neratinib in Early Breast Cancer Article Snippet: .. Biomarker assessments include the Agendia 70 gene MammaPrint and Phospho-proteomics:Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and other:Article Title: MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology. Article Snippet: Figure 7: Scatterplot comparison analysis of MammaPrint and BluePrint NGS indices (Luminal-, HER2-, Basal-types) assessed at |
